RU99114018A - SOMATOSTATIN ANTAGONISTS - Google Patents
SOMATOSTATIN ANTAGONISTSInfo
- Publication number
- RU99114018A RU99114018A RU99114018/04A RU99114018A RU99114018A RU 99114018 A RU99114018 A RU 99114018A RU 99114018/04 A RU99114018/04 A RU 99114018/04A RU 99114018 A RU99114018 A RU 99114018A RU 99114018 A RU99114018 A RU 99114018A
- Authority
- RU
- Russia
- Prior art keywords
- cys
- trp
- lys
- phe
- nal
- Prior art date
Links
- 229960000553 Somatostatin Drugs 0.000 title 1
- 102000005157 Somatostatin Human genes 0.000 title 1
- 108010056088 Somatostatin Proteins 0.000 title 1
- 230000003042 antagnostic Effects 0.000 title 1
- 239000005557 antagonist Substances 0.000 title 1
- NHXLMOGPVYXJNR-ATOGVRKGSA-N somatostatin Chemical compound C([C@H]1C(=O)N[C@H](C(N[C@@H](CO)C(=O)N[C@@H](CSSC[C@@H](C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CC=2C3=CC=CC=C3NC=2)C(=O)N[C@@H](CCCCN)C(=O)N[C@H](C(=O)N1)[C@@H](C)O)NC(=O)CNC(=O)[C@H](C)N)C(O)=O)=O)[C@H](O)C)C1=CC=CC=C1 NHXLMOGPVYXJNR-ATOGVRKGSA-N 0.000 title 1
- 125000000954 2-hydroxyethyl group Chemical group [H]C([*])([H])C([H])([H])O[H] 0.000 claims 67
- -1 aromatic amino acid Chemical class 0.000 claims 52
- 229910052736 halogen Inorganic materials 0.000 claims 50
- 150000002367 halogens Chemical group 0.000 claims 50
- QLNJFJADRCOGBJ-UHFFFAOYSA-N Propanamide Chemical compound CCC(N)=O QLNJFJADRCOGBJ-UHFFFAOYSA-N 0.000 claims 34
- 150000001875 compounds Chemical class 0.000 claims 30
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 claims 29
- 125000000217 alkyl group Chemical group 0.000 claims 11
- 125000000510 L-tryptophano group Chemical group [H]C1=C([H])C([H])=C2N([H])C([H])=C(C([H])([H])[C@@]([H])(C(O[H])=O)N([H])[*])C2=C1[H] 0.000 claims 9
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 claims 8
- QIVBCDIJIAJPQS-SECBINFHSA-N D-tryptophane Chemical compound C1=CC=C2C(C[C@@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-SECBINFHSA-N 0.000 claims 7
- 125000000267 glycino group Chemical group [H]N([*])C([H])([H])C(=O)O[H] 0.000 claims 7
- OUYCCCASQSFEME-MRVPVSSYSA-N D-tyrosine Chemical compound OC(=O)[C@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-MRVPVSSYSA-N 0.000 claims 6
- 150000003839 salts Chemical class 0.000 claims 6
- 239000011780 sodium chloride Substances 0.000 claims 6
- UCMIRNVEIXFBKS-UHFFFAOYSA-N β-Alanine Chemical compound NCCC(O)=O UCMIRNVEIXFBKS-UHFFFAOYSA-N 0.000 claims 6
- COLNVLDHVKWLRT-MRVPVSSYSA-N D-phenylalanine Chemical compound OC(=O)[C@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-MRVPVSSYSA-N 0.000 claims 5
- XUJNEKJLAYXESH-REOHCLBHSA-N L-cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 claims 5
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 claims 4
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 4
- XUJNEKJLAYXESH-UWTATZPHSA-N D-cysteine Chemical compound SC[C@@H](N)C(O)=O XUJNEKJLAYXESH-UWTATZPHSA-N 0.000 claims 3
- HNDVDQJCIGZPNO-RXMQYKEDSA-N D-histidine Chemical compound OC(=O)[C@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-RXMQYKEDSA-N 0.000 claims 3
- 125000003118 aryl group Chemical group 0.000 claims 3
- 125000000623 heterocyclic group Chemical group 0.000 claims 3
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 claims 2
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 2
- 125000004203 4-hydroxyphenyl group Chemical group [H]OC1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 1
- 239000004215 Carbon black (E152) Substances 0.000 claims 1
- 150000008574 D-amino acids Chemical class 0.000 claims 1
- 150000008575 L-amino acids Chemical class 0.000 claims 1
- NQIHMZLGCZNZBN-PXNSSMCTSA-N Trp-Trp Chemical compound C1=CC=C2C(C[C@H](NC(=O)[C@H](CC=3C4=CC=CC=C4NC=3)N)C(O)=O)=CNC2=C1 NQIHMZLGCZNZBN-PXNSSMCTSA-N 0.000 claims 1
- 125000003545 alkoxy group Chemical group 0.000 claims 1
- 125000006297 carbonyl amino group Chemical group [H]N([*:2])C([*:1])=O 0.000 claims 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims 1
- 150000002430 hydrocarbons Chemical class 0.000 claims 1
- 239000000126 substance Substances 0.000 claims 1
- 125000001424 substituent group Chemical group 0.000 claims 1
Claims (31)
где A1 представляет D- или L-изомер ароматической аминокислоты, или отсутствует;
A2 представляет D-изомер, выбранный из группы, включающей Cys, Pen, ароматическую аминокислоту или алифатическую аминокислоту;
A3 представляет ароматическую аминокислоту;
A4 представляет Тrр или D-Trp;
A6 представляет Thr, Thr(Bzl), Gly, Ser, Eaa или алифатическую аминокислоту;
A7 представляет Cys, Pen или ароматическую или алифатическую аминокислоту;
A8 представляет D- или L-изомер, выбранный из группы, включающей Thr, Ser, ароматическую аминокислоту или алифатическую аминокислоту;
каждый из R1, и R2 независимо представляет Н или замещенный или незамещенный низший алкил, арил, арил-низший алкил, гетероцикл, гетероцикл низший алкил, E1SO2 или Е1СО (где Е представляет арил, арил-низший алкил, гетероцикл или гетероцикл низший алкил), где указанный заместитель является галогеном, низшим алкилом, гидроксилом, галоген низшим алкилом или гидрокси низшим алкилом; и
R3 представляет ОН, NH2, C1-12 алкокси или NH-Y-CH2-Z, где Y представляет С1-12 углеводородную часть и Z представляет Н, ОН, СО2Н или CONH2, или R3, вместе с карбонильной группой А8, присоединенной к нему, восстановлены до Н, низшего алкила или гидрокси низшего алкила; при условии, что, если А2 является D-Cys или D-Pen, и А7 является Cys или Реn, то боковые цепи А2 и А7 связаны дисульфидной связью, и если А1 является D-Phe или п-NO2-Phe, А2 представляет D-Cys, А3 представляет Phe или Тyr, А6 представляет Thr или Val и А7 представляет Cys, то А8 представляет β-Nal.1. The substance according to the formula:
where A 1 is the D- or L-isomer of an aromatic amino acid, or is absent;
A 2 is a D-isomer selected from the group consisting of Cys, Pen, an aromatic amino acid or an aliphatic amino acid;
A 3 is an aromatic amino acid;
A 4 is Trp or D-Trp;
A 6 is Thr, Thr (Bzl), Gly, Ser, Eaa, or an aliphatic amino acid;
A 7 is Cys, Pen, or an aromatic or aliphatic amino acid;
A 8 is a D- or L-isomer selected from the group consisting of Thr, Ser, an aromatic amino acid, or an aliphatic amino acid;
each of R 1 and R 2 independently represents H or substituted or unsubstituted lower alkyl, aryl, aryl-lower alkyl, heterocycle, heterocycle lower alkyl, E 1 SO 2 or E 1 CO (where E is aryl, aryl-lower alkyl, heterocycle or lower alkyl heterocycle), where said substituent is halogen, lower alkyl, hydroxyl, halogen lower alkyl, or hydroxy lower alkyl; and
R 3 is OH, NH 2 , C 1-12 alkoxy, or NH-Y — CH 2 -Z, where Y is a C 1-12 hydrocarbon portion and Z is H, OH, CO 2 H or CONH 2 , or R 3 , together with the carbonyl group A 8 attached to it, reduced to H, lower alkyl or hydroxy lower alkyl; provided that if A 2 is D-Cys or D-Pen, and A 7 is Cys or Pe, then the side chains of A 2 and A 7 are linked by a disulfide bond, and if A 1 is D-Phe or p-NO 2 -Phe, A 2 is D-Cys, A 3 is Phe or Tyr, A 6 is Thr or Val and A 7 is Cys, then A 8 is β-Nal.
H2-β-Nal-D-Cys-Tyr-D-Trp-Lys-Val-Cys-β-Nal-NH2;
(H)(CH3CO)-β-Nal-D-Cys-Tyr-D-Trp-Lys-Val-Cys-β-Nal-NH2 (V);
(Н) - (4- (2-гидроксиэтил)-1-пиперазинилацетил) -β-Nal-D-Cys-Tyr-D-Trp-Lys-Val-Cys-β-Nal-NH2;
(H) - (4- (2-гидроксиэтил)-1-пиперазинэтансульфонил) -β-Nal-D-Cys-Tyr-D-Trp-Lys-Val-Cys-β-Nal-NH2;
H2-β-Nal-D-Cуs-Pal-D-Trp-Lуs-Val-Cуs-β-Nal-NH2;
(H)(CH3CO)-β-Nal-D-Cys-Pal-D-Trp-Lys-Val-Cys-β-Nal-NH2;
(H) - (4- (2-гидроксиэтил) -1-пиперазинилацетил) -β-Nal-D-Cys-Pal-D-Trp-Lys-Val-Cys-β-Nal-NH2;
(H) - (4- (2-гидроксиэтил) -1-пиперазинэтансульфонил) -β-Nal-D-Cys-Pal-D-Trp-Lys-Val-Cys-β-Nal-NH2;
H2-β-Nal-D-Cys-Tyr-D-Trp-Lys-Val-Cys-Thr-NH2;
(H) (CH3CO)-β-Nal-D-Cys-Tyr-D-Trp-Lys-Val-Cys-Thr-NH2;
(H)-(4- (2-гидроксиэтил) -1-пиперазинилацетил) -β-Nal-D-Cys-Tyr-D-Trp-Lys-Val-Cys-Thr-NH2;
(H)-(4- (2-гидроксиэтил)-1-пиперазинэтансульфонил)-β-Nal-D-Cys-Туг-D-Trp-Lys-Val-Cys-Thr-NH2;
H2-β-Nal-D-Cys-Pal-D-Trp-Lys-Val-Cys-Thr-NH2;
(H)(CH3CO)-β-Nal-D-Cys-Pal-D-Trp-Lys-Val-Cys-Thr-NH2;
(H) (4-(2-гидроксиэтил)-1-пиперазинилацетил)-β-Nal-D-Cys-Pal-D-Trp-Lys-Val-Cys-Thr-NH2;
H2-Phe-D-Cys-Tyr-D-Trp-Lys-Val-Cys-β-Nal-NH2;
(H) (CH3CO)-Phe-D-Cys-Tyr-D-Trp-Lys-Val-Cys-β-Nal-NH2;
(H) (4-(2-гидроксиэтил)-1-пиперазинилацетил)-Рhе-D-Суs-Tyr-D-Trp-Lys-Val-Cys-β-Nal-NH2;
(H) (4-(2-гидроксиэтил)-1-пиперазинэтансульфонил)-Рhе-D-Cys-Tyr-D-Trp-Lys-Val-Cys-β-Nal-NH2;
H2-Phe-D-Cys-Pal-D-Trp-Lys-Val-Cys-β-Nal-NH2;
(H)(CH3CO)-Phe-D-Cys-Pal-D-Trp-Lys-Val-Cys-β-Nal-NH2;
(H) (4-(2-гидроксиэтил)-1-пиперазинилацетил)-Рhе-D-Суs-Pal-D-Trp-Lys-Val-Cys-β-Nal-NH2;
(H) (4-(2-гидроксиэтил)-1-пиперазинэтансульфонил)-Рhе-D-Cys-Pal-D-Trp-Lys-Val-Cys-β-Nal-NH2;
H2-Phe-D-Cys-Pal-D-Trp-Lys-Val-Cys-Thr-NH2;
(H)(CH3CO)-Phe-D-Cys-Pal-D-Trp-Lys-Val-Cys-Thr-NH2;
(H) (4-(2-гидроксиэтил)-1-пиперазинилацетил)-Рhе-D-Суs-Pal-D-Trp-Lys-Val-Cys-Thr-NH2;
(Н)(4-(2-гидроксиэтил)-1-пиперазинэтансульфонил)-Рhе-D- Cys-Pal-D-Trp-Lys-Val-Cys-Thr-NH2;
H2-β-Nal-D-Cys-Tyr-D-Trp-Lys-Thr-Cys-β-Nal-NH2;
(H) (CH3CO)-β-Nal-D-Cys-Pal-D-Trp-Lys-Thr-Cys-β-Nal-NH2;
(H) (4- (2-гидроксиэтил) -1-пиперазинилацетил)-β-Nal-D-Cys -Tyr-D-Trp-Lys-Thr-Cys-β-Nal-NH2;
(H) (4-(2-гидроксиэтил)-1-пиперазинэтансульфонил)-β-Nal -D-Cys-Tyr-D-Trp-Lys-Thr-Cys-β-Nal-NH2;
H2-β-Nal-D-Cys-Pal-D-Trp-Lys-Thr-Cys-β-Nal-NH2;
(H) (СH3СО) -β-Nal-D-Cys-Pal-D-Trp-Lys-Thr-Cys-β-Nal-NH2;
(H) (4- (2-гидроксиэтил) -1-пиперазинилацетил) -β-Nal-D-Cys -Pal-D-Trp-Lys-Thr-Cys-β-Nal-NH2;
(H) (4- (2-гидроксиэтил) -1-пиперазинэтансульфонил) -β-Nal-D-Cys-Pal-D-Trp-Lys-Thr-Cys-β-Nal-NH2;
H2-β-Nal-D-Cys-Tyr-D-Trp-Lys-Thr-Cys-Thr-NH2;
(H) (СH3СО)- β-Nal-D-Cys-Tyr-D-Trp-Lys-Thr-Cys-Thr-NH2;
(H) (4- (2-гидроксиэтил) -1-пиперазинилацетил) -β-Nal-D-Cys -Tyr-D-Trp-Lys-Thr-Cys-Thr-NH2;
(H) (4- (2-гидроксиэтил) -1-пиперазинэтансульфонил) -β-Nal-D-Cys-Tyr-D-Trp-Lys-Thr-Cys-Thr-NH2;
H2-β-Nal-D-Cys-Pal-D-Trp-Lys-Thr-Cys-Thr-NH2;
(H) (СH3СО) -β-Nal-D-Cys-Pal-D-Trp-Lys-Thr-Cys-Thr-NH2;
(H) (4- (2-гидроксиэтил) -1-пиперазинилацетил)-β-Nal-D-Сys -Pal-D-Trp-Lys-Thr-Cys-Thr-NH2;
(Н) (4- (2-гидроксиэтил) -1-пиперазинэтансульфонил) -β-Nal-D-Cys-Pal-D-Trp-Lys-Thr-Cys-Thr-NH2;
H2-Phe-D-Cys-Tyr-D-Trp-Lys-Thr-Cys-β-Nal-NH2;
(H) (СH3СО) -Phe-D-Cys-Tyr-D-Trp-Lys-Thr-Cys-β-Nal-NH2;
(Н) (4- (2-гидроксиэтил) -1-пиперазинилацетил) -Phe-D-Cys-Tyr-D-Trp-Lys-Thr-Cys-β-Nal-NH2;
(Н) (4- (2-гидроксиэтил) -l-пипepaзинэтaнcульфoнил) -Phe-D-Cys-Tyr-D-Trp-Lys-Thr-Cys-β-Nal-NH2;
H2-Phe-D-Cys-Pal-D-Trp-Lys-Thr-Cys-β-Nal-NH2;
(Н) (СH3СО) -Phe-D-Cys-Pal-D-Trp-Lys-Thr-Cys-β-Nal-NH2;
(H) (4- (2-гидроксиэтил) -1-пиперазинилацетил) -Phe-D-Cys-Pal-D-Trp-Lys-Thr-Cys-β-Nal-NH2;
(H) (4- (2-гидроксиэтил) -1-пиперазинэтансульфонил) -Phe-D-Cys-Pal-D-Trp-Lys-Thr-Cys-β-Nal-NH2;
H2-Phe-D-Cys-Tyr-D-Trp-Lys-Thr-Cys-Thr-NH2;
(H) (СH3СО) -Phe-D-Cys-Tyr-D-Trp-Lys-Thr-Cys-Thr-NH2;
(H) (4- (2-гидpoкcиэтил) -1-пиперазинилацетил) -Phe-D-Cys-Tyr-D-Tip-Lys-Thr-Cys-Thr-NH2;
(H) (4- (2-гидроксиэтил) -1-пиперазинэтансульфонил) -Phe-D-Cys-Tyr-D-Trp-Lys-Thr-Cys-Thr-NH2;
H2-Phe-D-Cys-Pal-D-Trp-Lys-Thr-Cys-Thr-NH2 (аналог 6);
(H) (СH3СО)-Phe-D-Cys-PaL-D-Trp-Lys-Thr-Cys-Thr-NH2;
(H) (4- (2-гидроксиэтил) -1-пиперазинилацетил) -Phe-D-Cys-Pal-D-Trp-Lys-Thr-Cys-Thr-NH2;
(H) (4- (2-гидроксиэтил) -1-пиперазинэтансульфонил)-Рhе-D-Cys-Pal-D-Trp-Lys-Thr-Cys-Thr-NH2;
H2-β-Nal-D-Cys-Tyr-D-Trp-Lys-Abu-Cys-β-Nal-NH2;
H2-Phe-D-Cys-Tyr-D-Trp-Lys-Abu-Cys-β-Nal-NH2;
H2-β-Nal-D-Cys-Pal-D-Trp-Lys-Abu-Cys-β-Nal-NH2;
H2-Phe-D-Cys-Pal-D-Trp-Lys-Abu-Cys-β-Nal-NH2;
H2-β-Nal-D-Cys-Tyr-D-Trp-Lys-Abu-Cys-Thr-NH2;
H2-Phe-D-Pen-Tyr-D-Trp-Lys-Val-Pen-β-Nal-NH2; или
H2-Phe-D-Pen-Pal-D-Trp-Lys-Thr-Pen-Thr-NH2;
H2-Dip-D-Cys-Pal-D-Trp-Lys-Val-Cys-Dip-NH2;
H2-F5-Phe-D-Cys-His-D-Trp-Lys-Val-Cys-F5-Phe-NH2;
H2-Dip-D-Cys-Pal-D-Trp-Lys-Val-Cys-β-Nal-NH2;
H2-м-F-Phe-D-Pen-Pal-D-Trp-Lys-Val-Cys-м-F-Phe-NH2;
H2-o-F-Phe-D-Cys-Pal-D-Trp-Lys-Val-Cys-o-F-Phe-NH2;
H2-п-p-Phe-D-Cys-Pal-D-Trp-Lys-Val-Cys-п-F-Phe-NH2;
H2-F5-Phe-D-Cys-Pal-D-Trp-Lys-Val-Cys-F5-Phe-NH2;
H2-F5-Phe-D-Cys-2-Pal-D-Trp-Lys-Val-Cys-F5-Phe-NH2;
H2-β-Nal-D-Cys-His-D-Trp-Lys-Val-Cys-D-Dip-NH2;
H2-Dip-D-Cys-His-D-Trp-Lys-Val-Cys-β-Nal-NH2;
H2-Dip-D-Cys-His-D-Trp-Lys-Val-Cys-Dip-NH2;
H2-β-Nal-D-Cys-His-D-Trp-Lys-Val-Cys-β-Nal-NH2;
H2-Trp-D-Cys-Tyr-D-Trp-Lys-Val-Cys-D-β-Nal-NH2;
H2-β-Nal-D-Cys-Tyr-D-Trp-Lys-Val-Cys-D-β-Nal-NH2;
H2-β-Nal-D-Cys-Pal-D-Trp-Lys-Val-Cys-D-п-F-Phe-NH2;
H2-β-Nal-D-Cys-Pal-D-Trp-Lys-Val-Cys-β-Nal-NH2;
H2-п-F-Phe-D-Cys-Pal-D-Trp-Lys-Val-Cys-β-Nal-NH2;
H2-β-Nal-D-Cys-Pal-D-Trp-Lys-Nle-Cys-β-Nal-NH2;
H2-β-Nal-D-Cys-Pal-D-Trp-Lys-Ile-Cys-β-Nal-NH2;
H2-β-Nal-D-Cys-Pal-D-Trp-Lys-Gly-Cys-β-Nal-NH2;
H2-β-Nal-D-Cys-Pal-D-Trp-Lys-Ala-Cys-β-Nal-NH2;
H2-β-Nal-D-Cys-Pal-D-Trp-Lys-Leu-Cys-β-Nal-NH2;
H2-Bip-D-Cys-Tyr-D-Trp-Lys-Ile-Cys-Bip-NH2;
H2-п-F-Phe-D-Cys-His-D-Trp-Lys-Val-Cys-п-F-Phe-NH2;
H2-Npa-D-Cys-Pal-D-Trp-Lys-Val-Cys-Tyr-NH2;
H2-м-F-Phe-D-Cys-His-D-Trp-Lys-Val-Cys-м-F-Phe-NH2;
H2-o-F-Phe-D-Cys-His-D-Trp-Lys-Val-Cys-o-F-Phe-NH2;
H2-β-Nal-D-Cys-Pal-D-Trp-Lys-Nle-Cys-Dip-NH2;
H2-Cpa-D-Cys-Pal-D-Trp-Lys-Val-Cys-Cpa-NH2;
H2-Igl-D-Cys-Pal-D-Trp-Lys-Val-Cys-Igl-NH2;
H2-β-Nal-D-Cys-Pal-D-Trp-Lys-Val-Cys-D-Dip-NH2;
H2-β-Nal-D-Cys-3-I-Tyr-D-Trp-Lys-Val-Cys-β-Nal-NH2;
H2-п-CN-Phe-D-Cys-Pal-D-Trp-Lys-Val-Cys-п-CN-Phe-NH2;
H2-β-Nal-D-Cys-Tyr-D-Trp-Lys-Val-Cys-D-Dip-NH2;
H2-β-Nal-D-Cys-Bta-D-Trp-Lys-Vyl-Cys-β-Nal-NH2;
H2-п-F-Phe-D-Cys-Pal-D-Trp-Lys-Tle-Cys-β-Nal-NH2;
H2-Bpa-D-Cys-Pal-D-Trp-Lys-Val-Cys-Bpa-NH2;
H2-Iph-D-Cys-Pal-D-Trp-Lys-Val-Cys-Iph-NH2;
H2-Trp-D-Cys-Pal-D-Trp-Lys-Tle-Cys-β-Nal-NH2;
H2-п-Cl-Phe-D-Cys-Pal-D-Trp-Lys-Val-Cys-β-Nal-NH2;
H2-п-Cl-Phe-D-Cys-Pal-D-Trp-Lys-Tle-Cys-β-Nal-NH2;
H2-п-Cl-Phe-D-Cys-Pal-D-Trp-Lys-Tle-Cys-п-Cl-Phe-NH2;
H2-п-Cl-Phe-D-Cys-Pal-D-Trp-Lys-Cha-Cys-п-Cl-Phe-NH2;
H2-п-Cl-Phe-D-Cys-Tyr(I)-D-Trp-Lys-Val-Cys-п-Cl-Phe-NH2;
H2-п-Cl-Phe-D-Cys-Tyr(I)-D-Trp-Lys-Val-Cys-β-Nal-NH2;
H2-п-Cl-Phe-D-Cys-Tyr(I)-D-Trp-Lys-Tle-Cys-β-Nal-NH2;
H2-п-F-Phe-D-Cys-Tyr(I)-D-Trp-Lys-Val-Cys-β-Nal-NH2;
H2-п-F-Phe-D-Cys-Tyr(I)-D-Trp-Lys-Tle-Cys-β-Nal-NH2;
H2-β-Nal -D-Cys -Туr- D-Trp-Lys-Abu-Cys-β-Nal-NH2;
(H) (СH3СО)-β-Nal-D-Cys-Tyr-D-Trp-Lys-Abu-Cys-β-Nal-NH2;
H2-п-NO2- Phe-D-Cys -Тyr-D-Trp-Lys -Abu-Cys-β-Nal -NH2;
(H) (СH3СО)-п-NO2- Phe-D-Cys-Tyr-D-Trp-Lys-Abu-Cys-β-Nal-NH2;
H2-п-NO2-Phe-D-Cys-Tyr-(Bzl) -D-Trp-Lys-Thr (Bzl) -Cys-β-Nal-NH2;
(H) (4- (2-гидроксиэтил) -l-пипepaзинилaцeтил)-п-NO2-Phe-D-Cys-Tyr (Bzl)-D-Trp-Lys-Thr(Bzl)-Cys-β-Nal-NH2;
(H) (4- (2-гидроксиэтил) -1-пиперазинилацетил)-п-NO2-Phe D-Cys-Tyr-D-Trp-Lys-Thr-Cys-Tyr-NH2;
H2-п-NO2-Phe-D-Cys-Tyr-D-Trp-Lys-Val-Cys-β-Nal-NH2;
(H) (4- (2-гидроксиэтил) -1-пиперазинилацетил)-п-NO2-Phe-D-Cys-Tyr-D-Trp-Lys-Val-Cys-β-Nal-NH2;
(H) (4- (2-гидроксиэтил) -1-пиперазинилацетил)-β-Nal-Phe-D-Cys-Tyr-D-Trp-Lys-Val-Cys-β-Nal-NH2;
H2-β-Nal-D-Cys-Tyr (Bzl)-D-Trp-Lys-Thr (Bzl)-Cys-β-Nal-NH2;
(H) (4- (2-гидроксиэтил) -1-пиперазинилацетил)-β-Nal-D-Cys-Туг (Bzl) -D-Trp-Lys-Thr (Bzl)-Cys-β-Nal-NH2;
или его фармацевтически приемлемая соль.7. The compound according to claim 4 of the formula:
H 2 -β-Nal-D-Cys-Tyr-D-Trp-Lys-Val-Cys-β-Nal-NH 2 ;
(H) (CH 3 CO) -β-Nal-D-Cys-Tyr-D-Trp-Lys-Val-Cys-β-Nal-NH 2 (V);
(H) - (4- (2-hydroxyethyl) -1-piperazinyl acetyl) -β-Nal-D-Cys-Tyr-D-Trp-Lys-Val-Cys-β-Nal-NH 2 ;
(H) - (4- (2-hydroxyethyl) -1-piperazine ethanesulfonyl) -β-Nal-D-Cys-Tyr-D-Trp-Lys-Val-Cys-β-Nal-NH 2 ;
H 2 -β-Nal-D-Cуs-Pal-D-Trp-Lуs-Val-Cуs-β-Nal-NH 2 ;
(H) (CH 3 CO) -β-Nal-D-Cys-Pal-D-Trp-Lys-Val-Cys-β-Nal-NH 2 ;
(H) - (4- (2-hydroxyethyl) -1-piperazinylacetyl) -β-Nal-D-Cys-Pal-D-Trp-Lys-Val-Cys-β-Nal-NH 2 ;
(H) - (4- (2-hydroxyethyl) -1-piperazine ethanesulfonyl) -β-Nal-D-Cys-Pal-D-Trp-Lys-Val-Cys-β-Nal-NH 2 ;
H 2 -β-Nal-D-Cys-Tyr-D-Trp-Lys-Val-Cys-Thr-NH 2 ;
(H) (CH 3 CO) -β-Nal-D-Cys-Tyr-D-Trp-Lys-Val-Cys-Thr-NH 2 ;
(H) - (4- (2-hydroxyethyl) -1-piperazinyl acetyl) -β-Nal-D-Cys-Tyr-D-Trp-Lys-Val-Cys-Thr-NH 2 ;
(H) - (4- (2-hydroxyethyl) -1-piperazine ethanesulfonyl) -β-Nal-D-Cys-Tug-D-Trp-Lys-Val-Cys-Thr-NH 2 ;
H 2 -β-Nal-D-Cys-Pal-D-Trp-Lys-Val-Cys-Thr-NH 2 ;
(H) (CH 3 CO) -β-Nal-D-Cys-Pal-D-Trp-Lys-Val-Cys-Thr-NH 2 ;
(H) (4- (2-hydroxyethyl) -1-piperazinylacetyl) -β-Nal-D-Cys-Pal-D-Trp-Lys-Val-Cys-Thr-NH 2 ;
H 2 -Phe-D-Cys-Tyr-D-Trp-Lys-Val-Cys-β-Nal-NH 2 ;
(H) (CH 3 CO) -Phe-D-Cys-Tyr-D-Trp-Lys-Val-Cys-β-Nal-NH 2 ;
(H) (4- (2-hydroxyethyl) -1-piperazinylacetyl) -Phe-D-Cys-Tyr-D-Trp-Lys-Val-Cys-β-Nal-NH 2 ;
(H) (4- (2-hydroxyethyl) -1-piperazine ethanesulfonyl) -Phe-D-Cys-Tyr-D-Trp-Lys-Val-Cys-β-Nal-NH 2 ;
H 2 -Phe-D-Cys-Pal-D-Trp-Lys-Val-Cys-β-Nal-NH 2 ;
(H) (CH 3 CO) -Phe-D-Cys-Pal-D-Trp-Lys-Val-Cys-β-Nal-NH 2 ;
(H) (4- (2-hydroxyethyl) -1-piperazinylacetyl) -Phe-D-Cys-Pal-D-Trp-Lys-Val-Cys-β-Nal-NH 2 ;
(H) (4- (2-hydroxyethyl) -1-piperazine ethanesulfonyl) -Phe-D-Cys-Pal-D-Trp-Lys-Val-Cys-β-Nal-NH 2 ;
H 2 -Phe-D-Cys-Pal-D-Trp-Lys-Val-Cys-Thr-NH 2 ;
(H) (CH 3 CO) -Phe-D-Cys-Pal-D-Trp-Lys-Val-Cys-Thr-NH 2 ;
(H) (4- (2-hydroxyethyl) -1-piperazinylacetyl) -Phe-D-Cys-Pal-D-Trp-Lys-Val-Cys-Thr-NH 2 ;
(H) (4- (2-hydroxyethyl) -1-piperazine ethanesulfonyl) -Phe-D-Cys-Pal-D-Trp-Lys-Val-Cys-Thr-NH 2 ;
H 2 -β-Nal-D-Cys-Tyr-D-Trp-Lys-Thr-Cys-β-Nal-NH 2 ;
(H) (CH 3 CO) -β-Nal-D-Cys-Pal-D-Trp-Lys-Thr-Cys-β-Nal-NH 2 ;
(H) (4- (2-hydroxyethyl) -1-piperazinylacetyl) -β-Nal-D-Cys -Tyr-D-Trp-Lys-Thr-Cys-β-Nal-NH 2 ;
(H) (4- (2-hydroxyethyl) -1-piperazine ethanesulfonyl) -β-Nal-D-Cys-Tyr-D-Trp-Lys-Thr-Cys-β-Nal-NH 2 ;
H 2 -β-Nal-D-Cys-Pal-D-Trp-Lys-Thr-Cys-β-Nal-NH 2 ;
(H) (CH 3 CO) -β-Nal-D-Cys-Pal-D-Trp-Lys-Thr-Cys-β-Nal-NH 2 ;
(H) (4- (2-hydroxyethyl) -1-piperazinyl acetyl) -β-Nal-D-Cys-Pal-D-Trp-Lys-Thr-Cys-β-Nal-NH 2 ;
(H) (4- (2-hydroxyethyl) -1-piperazine ethanesulfonyl) -β-Nal-D-Cys-Pal-D-Trp-Lys-Thr-Cys-β-Nal-NH 2 ;
H 2 -β-Nal-D-Cys-Tyr-D-Trp-Lys-Thr-Cys-Thr-NH 2 ;
(H) (CH 3 CO) - β-Nal-D-Cys-Tyr-D-Trp-Lys-Thr-Cys-Thr-NH 2 ;
(H) (4- (2-hydroxyethyl) -1-piperazinylacetyl) -β-Nal-D-Cys -Tyr-D-Trp-Lys-Thr-Cys-Thr-NH 2 ;
(H) (4- (2-hydroxyethyl) -1-piperazine ethanesulfonyl) -β-Nal-D-Cys-Tyr-D-Trp-Lys-Thr-Cys-Thr-NH 2 ;
H 2 -β-Nal-D-Cys-Pal-D-Trp-Lys-Thr-Cys-Thr-NH 2 ;
(H) (CH 3 CO) -β-Nal-D-Cys-Pal-D-Trp-Lys-Thr-Cys-Thr-NH 2 ;
(H) (4- (2-hydroxyethyl) -1-piperazinyl acetyl) -β-Nal-D-Cys-Pal-D-Trp-Lys-Thr-Cys-Thr-NH 2 ;
(H) (4- (2-hydroxyethyl) -1-piperazine ethanesulfonyl) -β-Nal-D-Cys-Pal-D-Trp-Lys-Thr-Cys-Thr-NH 2 ;
H 2 -Phe-D-Cys-Tyr-D-Trp-Lys-Thr-Cys-β-Nal-NH 2 ;
(H) (CH 3 CO) -Phe-D-Cys-Tyr-D-Trp-Lys-Thr-Cys-β-Nal-NH 2 ;
(H) (4- (2-hydroxyethyl) -1-piperazinyl acetyl) -Phe-D-Cys-Tyr-D-Trp-Lys-Thr-Cys-β-Nal-NH 2 ;
(H) (4- (2-hydroxyethyl) -l-piperidazine ethanesulfonyl) -Phe-D-Cys-Tyr-D-Trp-Lys-Thr-Cys-β-Nal-NH 2 ;
H 2 -Phe-D-Cys-Pal-D-Trp-Lys-Thr-Cys-β-Nal-NH 2 ;
(H) (CH 3 CO) -Phe-D-Cys-Pal-D-Trp-Lys-Thr-Cys-β-Nal-NH 2 ;
(H) (4- (2-hydroxyethyl) -1-piperazinylacetyl) -Phe-D-Cys-Pal-D-Trp-Lys-Thr-Cys-β-Nal-NH 2 ;
(H) (4- (2-hydroxyethyl) -1-piperazine ethanesulfonyl) -Phe-D-Cys-Pal-D-Trp-Lys-Thr-Cys-β-Nal-NH 2 ;
H 2 -Phe-D-Cys-Tyr-D-Trp-Lys-Thr-Cys-Thr-NH 2 ;
(H) (CH 3 CO) -Phe-D-Cys-Tyr-D-Trp-Lys-Thr-Cys-Thr-NH 2 ;
(H) (4- (2-hydroxyethyl) -1-piperazinyl acetyl) -Phe-D-Cys-Tyr-D-Tip-Lys-Thr-Cys-Thr-NH 2 ;
(H) (4- (2-hydroxyethyl) -1-piperazine ethanesulfonyl) -Phe-D-Cys-Tyr-D-Trp-Lys-Thr-Cys-Thr-NH 2 ;
H 2 -Phe-D-Cys-Pal-D-Trp-Lys-Thr-Cys-Thr-NH 2 (analog 6);
(H) (CH 3 CO) -Phe-D-Cys-PaL-D-Trp-Lys-Thr-Cys-Thr-NH 2 ;
(H) (4- (2-hydroxyethyl) -1-piperazinylacetyl) -Phe-D-Cys-Pal-D-Trp-Lys-Thr-Cys-Thr-NH 2 ;
(H) (4- (2-hydroxyethyl) -1-piperazine ethanesulfonyl) -Phe-D-Cys-Pal-D-Trp-Lys-Thr-Cys-Thr-NH 2 ;
H 2 -β-Nal-D-Cys-Tyr-D-Trp-Lys-Abu-Cys-β-Nal-NH 2 ;
H 2 -Phe-D-Cys-Tyr-D-Trp-Lys-Abu-Cys-β-Nal-NH 2 ;
H 2 -β-Nal-D-Cys-Pal-D-Trp-Lys-Abu-Cys-β-Nal-NH 2 ;
H 2 -Phe-D-Cys-Pal-D-Trp-Lys-Abu-Cys-β-Nal-NH 2 ;
H 2 -β-Nal-D-Cys-Tyr-D-Trp-Lys-Abu-Cys-Thr-NH 2 ;
H 2 -Phe-D-Pen-Tyr-D-Trp-Lys-Val-Pen-β-Nal-NH 2 ; or
H 2 -Phe-D-Pen-Pal-D-Trp-Lys-Thr-Pen-Thr-NH 2 ;
H 2 -Dip-D-Cys-Pal-D-Trp-Lys-Val-Cys-Dip-NH 2 ;
H 2 -F 5 -Phe-D-Cys-His-D-Trp-Lys-Val-Cys-F 5 -Phe-NH 2 ;
H 2 -Dip-D-Cys-Pal-D-Trp-Lys-Val-Cys-β-Nal-NH 2 ;
H 2 -m-F-Phe-D-Pen-Pal-D-Trp-Lys-Val-Cys-m-F-Phe-NH 2 ;
H 2 -oF-Phe-D-Cys-Pal-D-Trp-Lys-Val-Cys-oF-Phe-NH 2 ;
H 2 -n-p-Phe-D-Cys-Pal-D-Trp-Lys-Val-Cys-p-F-Phe-NH 2 ;
H 2 -F 5 -Phe-D-Cys-Pal-D-Trp-Lys-Val-Cys-F 5 -Phe-NH 2 ;
H 2 -F 5 -Phe-D-Cys-2-Pal-D-Trp-Lys-Val-Cys-F 5 -Phe-NH 2 ;
H 2 -β-Nal-D-Cys-His-D-Trp-Lys-Val-Cys-D-Dip-NH 2 ;
H 2 -Dip-D-Cys-His-D-Trp-Lys-Val-Cys-β-Nal-NH 2 ;
H 2 -Dip-D-Cys-His-D-Trp-Lys-Val-Cys-Dip-NH 2 ;
H 2 -β-Nal-D-Cys-His-D-Trp-Lys-Val-Cys-β-Nal-NH 2 ;
H 2 -Trp-D-Cys-Tyr-D-Trp-Lys-Val-Cys-D-β-Nal-NH 2 ;
H 2 -β-Nal-D-Cys-Tyr-D-Trp-Lys-Val-Cys-D-β-Nal-NH 2 ;
H 2 -β-Nal-D-Cys-Pal-D-Trp-Lys-Val-Cys-D-p-F-Phe-NH 2 ;
H 2 -β-Nal-D-Cys-Pal-D-Trp-Lys-Val-Cys-β-Nal-NH 2 ;
H 2 -n-F-Phe-D-Cys-Pal-D-Trp-Lys-Val-Cys-β-Nal-NH 2 ;
H 2 -β-Nal-D-Cys-Pal-D-Trp-Lys-Nle-Cys-β-Nal-NH 2 ;
H 2 -β-Nal-D-Cys-Pal-D-Trp-Lys-Ile-Cys-β-Nal-NH 2 ;
H 2 -β-Nal-D-Cys-Pal-D-Trp-Lys-Gly-Cys-β-Nal-NH 2 ;
H 2 -β-Nal-D-Cys-Pal-D-Trp-Lys-Ala-Cys-β-Nal-NH 2 ;
H 2 -β-Nal-D-Cys-Pal-D-Trp-Lys-Leu-Cys-β-Nal-NH 2 ;
H 2 -Bip-D-Cys-Tyr-D-Trp-Lys-Ile-Cys-Bip-NH 2 ;
H 2 -n-F-Phe-D-Cys-His-D-Trp-Lys-Val-Cys-p-F-Phe-NH 2 ;
H 2 -Npa-D-Cys-Pal-D-Trp-Lys-Val-Cys-Tyr-NH 2 ;
H 2 -m-F-Phe-D-Cys-His-D-Trp-Lys-Val-Cys-m-F-Phe-NH 2 ;
H 2 -oF-Phe-D-Cys-His-D-Trp-Lys-Val-Cys-oF-Phe-NH 2 ;
H 2 -β-Nal-D-Cys-Pal-D-Trp-Lys-Nle-Cys-Dip-NH 2 ;
H 2 -Cpa-D-Cys-Pal-D-Trp-Lys-Val-Cys-Cpa-NH 2 ;
H 2 -Igl-D-Cys-Pal-D-Trp-Lys-Val-Cys-Igl-NH 2 ;
H 2 -β-Nal-D-Cys-Pal-D-Trp-Lys-Val-Cys-D-Dip-NH 2 ;
H 2 -β-Nal-D-Cys-3-I-Tyr-D-Trp-Lys-Val-Cys-β-Nal-NH 2 ;
H 2 -n-CN-Phe-D-Cys-Pal-D-Trp-Lys-Val-Cys-p-CN-Phe-NH 2 ;
H 2 -β-Nal-D-Cys-Tyr-D-Trp-Lys-Val-Cys-D-Dip-NH 2 ;
H 2 -β-Nal-D-Cys-Bta-D-Trp-Lys-Vyl-Cys-β-Nal-NH 2 ;
H 2 -n-F-Phe-D-Cys-Pal-D-Trp-Lys-Tle-Cys-β-Nal-NH 2 ;
H 2 -Bpa-D-Cys-Pal-D-Trp-Lys-Val-Cys-Bpa-NH 2 ;
H 2 -Iph-D-Cys-Pal-D-Trp-Lys-Val-Cys-Iph-NH 2 ;
H 2- Trp-D-Cys-Pal-D-Trp-Lys-Tle-Cys-β-Nal-NH 2 ;
H 2 -n-Cl-Phe-D-Cys-Pal-D-Trp-Lys-Val-Cys-β-Nal-NH 2 ;
H 2 -n-Cl-Phe-D-Cys-Pal-D-Trp-Lys-Tle-Cys-β-Nal-NH 2 ;
H 2 -n-Cl-Phe-D-Cys-Pal-D-Trp-Lys-Tle-Cys-p-Cl-Phe-NH 2 ;
H 2 -n-Cl-Phe-D-Cys-Pal-D-Trp-Lys-Cha-Cys-p-Cl-Phe-NH 2 ;
H 2 -n-Cl-Phe-D-Cys-Tyr (I) -D-Trp-Lys-Val-Cys-p-Cl-Phe-NH 2 ;
H 2 -n-Cl-Phe-D-Cys-Tyr (I) -D-Trp-Lys-Val-Cys-β-Nal-NH 2 ;
H 2 -n-Cl-Phe-D-Cys-Tyr (I) -D-Trp-Lys-Tle-Cys-β-Nal-NH 2 ;
H 2 -n-F-Phe-D-Cys-Tyr (I) -D-Trp-Lys-Val-Cys-β-Nal-NH 2 ;
H 2 -n-F-Phe-D-Cys-Tyr (I) -D-Trp-Lys-Tle-Cys-β-Nal-NH 2 ;
H 2 -β-Nal-D-Cys-Tu-D-Trp-Lys-Abu-Cys-β-Nal-NH 2 ;
(H) (CH 3 CO) -β-Nal-D-Cys-Tyr-D-Trp-Lys-Abu-Cys-β-Nal-NH 2 ;
H 2 -n-NO 2 - Phe-D-Cys -Tyr-D-Trp-Lys -Abu-Cys-β-Nal -NH 2 ;
(H) (CH 3 CO) -n-NO 2 - Phe-D-Cys-Tyr-D-Trp-Lys-Abu-Cys-β-Nal-NH 2 ;
H 2 -n-NO 2 -Phe-D-Cys-Tyr- (Bzl) -D-Trp-Lys-Thr (Bzl) -Cys-β-Nal-NH 2 ;
(H) (4- (2-hydroxyethyl) -l-piperazinyl acetyl) -p-NO 2 -Phe-D-Cys-Tyr (Bzl) -D-Trp-Lys-Thr (Bzl) -Cys-β-Nal- NH 2 ;
(H) (4- (2-hydroxyethyl) -1-piperazinyl acetyl) -p-NO 2 -Phe D-Cys-Tyr-D-Trp-Lys-Thr-Cys-Tyr-NH 2 ;
H 2 -n-NO 2 -Phe-D-Cys-Tyr-D-Trp-Lys-Val-Cys-β-Nal-NH 2 ;
(H) (4- (2-hydroxyethyl) -1-piperazinyl acetyl) -p-NO 2 -Phe-D-Cys-Tyr-D-Trp-Lys-Val-Cys-β-Nal-NH 2 ;
(H) (4- (2-hydroxyethyl) -1-piperazinyl acetyl) -β-Nal-Phe-D-Cys-Tyr-D-Trp-Lys-Val-Cys-β-Nal-NH 2 ;
H 2 -β-Nal-D-Cys-Tyr (Bzl) -D-Trp-Lys-Thr (Bzl) -Cys-β-Nal-NH 2 ;
(H) (4- (2-hydroxyethyl) -1-piperazinylacetyl) -β-Nal-D-Cys-Tug (Bzl) -D-Trp-Lys-Thr (Bzl) -Cys-β-Nal-NH 2 ;
or its pharmaceutically acceptable salt.
или 4-(2-гидроксиэтил)-1-пиперизинэтансульфонил; R2 представляет Н, и R3 представляет NH2.10. The compound according to claim 9, in which A 1 is D-β-Nal, D-Npa, D-Igl, D-Phe, D-p-F-Phe, D-Trp, D-p-Cl-Phe or Dpn-Phe; A 3 is Tyr, Tyr (I) or Pal; A 6 is Val, Tle, Nle, Ile or Leu; A 8 is p-F-Phe, P-Nal, Tyr, Dip, p-Cl-Phe, Igl or p-CN-Phe; R 1 is H, CH 3 CO, 4- (2-hydroxyethyl) -1-piperazinyl acetyl
or 4- (2-hydroxyethyl) -1-piperizine ethanesulfonyl; R 2 is H, and R 3 is NH 2 .
H2-D-Phe-D-Pen-Tyr-D-Trp-Lys-Val-Cys-Thr-NH2;
H2-D-β-Nal-D-Cys-Tyr-D-Trp-Lys-Val-Cys-Thr-NH2;
H2-D-β-Nal-D-Cys-Tyr-D-Trp-Lys-Val-Cys-β-Nal-NH2;
H2-D-β-Nal-D-Cys-Tyr-D-Trp-Lys-Thr-Cys-β-Nal-NH2;
H2-D-Phe-D-Cys-Pal-D-Trp-Lys-Cys-Cys-Thr-NH2;
H2-D-Phe-D-Cys-Tyr-D-Trp-Lys-Abu-Cys-Thr-NH2;
H2-D-β-Nal-D-Cys-Tyr-D-Trp-Lys-Abu-Cys-Thr-NH2;
H2-D-β-Nal-D-Cys-Tyr-D-Trp-Lys-Val-Cys-D-β-Nal-NH2;
H2-D-п-F-Phe-D-Cys-Pal-D-Trp-Lys-Val-Cys-D-п-F-Phe-NH2;
H2-D-Bip-D-Cys-Tyr-D-Trp-Lys-Val-Cys-β-Nal-NH2;
H2-D-Dip-D-Cys-Pal-D-Trp-Lys-Val-Cys-β-Nal-NH2;
H2-D-п-F-Phe-D-Cys-Pal-D-Trp-Lys-Tle-Cys-β-Nal-NH2;
H2-D-п-Cl-Phe-D-Cys-Pal-D-Trp-Lys-Tle-Cys-п-Cl-Phe-NH2;
п-NO2-D-Phe-D-Cys-Pal-D-Trp-Lys-Thr(Bzl)-Cys-Tyr(Bzl)-NH2;
п-NO2-D-Phe-D-Cys-Tyr(Bzl)-D-Trp-Lys-Val-Cys-Tyr(Bzl)-NH2;
(H)(4-(2-гидроксиэтил)-1-пиперазинилацетил)-п-NO2-D-Phe-D-Cys-Pal-D-Trp-Lys-Thr(Bzl)-Cys-Tyr(Bzl)-NH2;
(H)(4-(2-гидроксиэтил)-1-пиперазинилацетил)-п-NO2-D-Рhе-D-Cys-Tyr(Bzl)-D-Trp-Lys-Val-Cys-Tyr(Bzl)-NH2
или его фармацевтически приемлемая соль.12. The compound according to claim 8 of the formula:
H 2 -D-Phe-D-Pen-Tyr-D-Trp-Lys-Val-Cys-Thr-NH 2 ;
H 2 -D-β-Nal-D-Cys-Tyr-D-Trp-Lys-Val-Cys-Thr-NH 2 ;
H 2 -D-β-Nal-D-Cys-Tyr-D-Trp-Lys-Val-Cys-β-Nal-NH 2 ;
H 2 -D-β-Nal-D-Cys-Tyr-D-Trp-Lys-Thr-Cys-β-Nal-NH 2 ;
H 2 -D-Phe-D-Cys-Pal-D-Trp-Lys-Cys-Cys-Thr-NH 2 ;
H 2 -D-Phe-D-Cys-Tyr-D-Trp-Lys-Abu-Cys-Thr-NH 2 ;
H 2 -D-β-Nal-D-Cys-Tyr-D-Trp-Lys-Abu-Cys-Thr-NH 2 ;
H 2 -D-β-Nal-D-Cys-Tyr-D-Trp-Lys-Val-Cys-D-β-Nal-NH 2 ;
H 2 -D-p-F-Phe-D-Cys-Pal-D-Trp-Lys-Val-Cys-D-p-F-Phe-NH 2 ;
H 2 -D-Bip-D-Cys-Tyr-D-Trp-Lys-Val-Cys-β-Nal-NH 2 ;
H 2 -D-Dip-D-Cys-Pal-D-Trp-Lys-Val-Cys-β-Nal-NH 2 ;
H 2 -D-p-F-Phe-D-Cys-Pal-D-Trp-Lys-Tle-Cys-β-Nal-NH 2 ;
H 2 -D-p-Cl-Phe-D-Cys-Pal-D-Trp-Lys-Tle-Cys-p-Cl-Phe-NH 2 ;
p-NO 2 -D-Phe-D-Cys-Pal-D-Trp-Lys-Thr (Bzl) -Cys-Tyr (Bzl) -NH 2 ;
p-NO 2 -D-Phe-D-Cys-Tyr (Bzl) -D-Trp-Lys-Val-Cys-Tyr (Bzl) -NH 2 ;
(H) (4- (2-hydroxyethyl) -1-piperazinylacetyl) -p-NO 2 -D-Phe-D-Cys-Pal-D-Trp-Lys-Thr (Bzl) -Cys-Tyr (Bzl) - NH 2 ;
(H) (4- (2-hydroxyethyl) -1-piperazinylacetyl) -p-NO 2 -D-Phe-D-Cys-Tyr (Bzl) -D-Trp-Lys-Val-Cys-Tyr (Bzl) - NH 2
or its pharmaceutically acceptable salt.
(H)(3-фeнилпpoпиoнил)-D-Cуs-Tyr-D-Trp-Lys-Val-Cys-β-Nal-NH2;
(Н)(3-фeнилпpопиoнил)-D-Cys-Pal-D-Trp-Lys-Val-Cуs-β-Nal-NH2;
(Н)(3-фeнилпpопиoнил)-D-Cys-Tyr-D-Trp-Lys-Thr-Cys-β-Nal-NH2;
(Н)(3-фeнилпpопиoнил)-Н-Сys-Рal-D-Тrр-Lys-Thr-Cys-β-Nal-NH2;
(Н)(3-фeнилпpопиoнил)-D-Cys-Tyr-D-Trp-Lys-Val-Cys-Thr-NH2;
(Н)(3-фeнилпpопиoнил)-D-Cys-Pal-D-Trp-Lys-Val-Cys-Thr-NH2;
(Н)(3-фeнилпpопиoнил)-D-Сys-Тyr-D-Тrр-Lys-Thr-Cys-Thr-NH2;
(Н)(3-фeнилпpопиoнил)-D-Cys-Раl-D-Тrp-Lys-Тhr-Cys-Thr-NH2;
(Н)(3-[2-нафтил]пропионил)-D-Сys-Тyr-D-Тrp-Lys-Val-Cys-β-Nal-NH2;
(3-[2-нафтил]пропионил)-D-Cys-Раl-D-Тrp-Lys-Val-Cys-β-Nal-NH2;
(H)(3-[2-нaфтил]пpoпиoнил)-D-Cys-Tyr-D-Trp-Lуs-Thr-Cys-β-Nal-NH2;
(H)(3-[2-нaфтил]пpoпиoнил)-D-Cys-Pal-D-Trp-Lys-Thr-Cys-β-Nal-NH2;
(H)(3-[2-нaфтил]пpoпиoнил)-D-Cys-Tyr-D-Trp-Lys-Val-Cys-Thr-NH2;
(Н)(3-[2-нафтил]пропионил)-D-Сys-Раl-D-Тrp-Lys-Val-Cys-Thr-NH2;
(H)(3-[2-нафтил]пропионил)-D-Cys-Tyr-D-Trp-Lys-Thr-Cys-Thr-NH2;
(Н)(3-[2-нафтил]пропионил)-D-Сys-Раl-D-Тrр-Lys-Тhr-Сys-Thr-NH2;
(Н)(3-[п-гидроксифенил])-D-Сys-Тyr-D-Тrр-Lys-Val-Cys-β-Nal-NH2;
(Н)(3-нафтилпропионил)-D-Сys-Тyr-D-Тrр-Lys-Аbu-Cys-β-Nal-NH2;
(Н)(3-нафтилпропионил)-D-Сys-Тyr-D-Тrр-Lys-Аbu-Сys-Thr-NH2;
(H)(3-фeнилпpoпиoнил)-D-Cys-Tyr-D-Trp-Lys-Abu-Cys-β-Nal-NH2;
(Н)(3-фенилпропионил)-D-Сys-Тyr-D-Тrр-Lys-Аbu-Сys-Тhr-NH2;
или его фармацевтически приемлемая соль.17. The compound according to claim 14 of the formula:
(H) (3-phenyl-propionyl) -D-Cy-Tyr-D-Trp-Lys-Val-Cys-β-Nal-NH 2 ;
(H) (3-phenylpropion) -D-Cys-Pal-D-Trp-Lys-Val-Cys-β-Nal-NH 2 ;
(H) (3-phenylpropion) -D-Cys-Tyr-D-Trp-Lys-Thr-Cys-β-Nal-NH 2 ;
(H) (3-phenylpropion) -H-Cys-Pal-D-Trp-Lys-Thr-Cys-β-Nal-NH 2 ;
(H) (3-phenylpropion) -D-Cys-Tyr-D-Trp-Lys-Val-Cys-Thr-NH 2 ;
(H) (3-phenylpropion) -D-Cys-Pal-D-Trp-Lys-Val-Cys-Thr-NH 2 ;
(H) (3-phenylpropion) -D-Cys-Tyr-D-Trp-Lys-Thr-Cys-Thr-NH 2 ;
(H) (3-phenyl propionyl) -D-Cys-Рal-D-Trp-Lys-Thr-Cys-Thr-NH 2 ;
(H) (3- [2-Naphthyl] propionyl) -D-Cys-Tyr-D-Trp-Lys-Val-Cys-β-Nal-NH 2 ;
(3- [2-naphthyl] propionyl) -D-Cys-PAL-D-Trp-Lys-Val-Cys-β-Nal-NH 2 ;
(H) (3- [2-naphthyl] propionyl) -D-Cys-Tyr-D-Trp-Lуs-Thr-Cys-β-Nal-NH 2 ;
(H) (3- [2-naphthyl] propionyl) -D-Cys-Pal-D-Trp-Lys-Thr-Cys-β-Nal-NH 2 ;
(H) (3- [2-naphthyl] propionyl) -D-Cys-Tyr-D-Trp-Lys-Val-Cys-Thr-NH 2 ;
(H) (3- [2-Naphthyl] propionyl) -D-Cys-Pall-D-Trp-Lys-Val-Cys-Thr-NH 2 ;
(H) (3- [2-Naphthyl] propionyl) -D-Cys-Tyr-D-Trp-Lys-Thr-Cys-Thr-NH 2 ;
(H) (3- [2-Naphthyl] propionyl) -D-Сys-Рal-D-Трр-Lys-Тhr-Сys-Thr-NH 2 ;
(H) (3- [p-hydroxyphenyl]) - D-Cys-Tyr-D-Trp-Lys-Val-Cys-β-Nal-NH 2 ;
(H) (3-naphthylpropionyl) -D-Cys-Tyr-D-Trp-Lys-Abu-Cys-β-Nal-NH 2 ;
(H) (3-naphthylpropionyl) -D-Cys-Tyr-D-Trp-Lys-Abu-Cys-Thr-NH 2 ;
(H) (3-phenylpropionyl) -D-Cys-Tyr-D-Trp-Lys-Abu-Cys-β-Nal-NH 2 ;
(H) (3-Phenylpropionyl) -D-Cys-Tyr-D-Trp-Lys-Abu-Cys-Thr-NH 2 ;
or its pharmaceutically acceptable salt.
H2-β-Nal-D-Cys-Tyr-D-Trp-Lys-Val-Cys-2R, 3R-(2-гидроксиметил)-3-гидрокси)пропиламид;
(Н) (СH3СО)-β-Nal-D-Cys-Tyr-D-Trp-Lys-Val-Cys-2R,3R-(2-гидроксиметил)-3-гидрокси)пропиламид;
(Н)(4-(2-гидроксиэтил)-1-пиперазинилацетил)-β-Nal-D-Cys-Tyr-D-Trp-Lys-Val-Cys-2R,3R-(2-гидроксиметил)-3-гидрокси)-пропиламид;
(Н)(4-(2-гидроксиэтил)-1-пиперизинэтансyльфонил)-β-Nal-D-Сys-Тyr-D-Тrр-Lys-Vаl-Сys-2R,3R-(2-гидроксиметил)-3-гидрокси)пропиламид;
H2 -β-Nal-D-Cys-Pal-D-Trp-Lys-Val-Cys-2R, 3R-(2-гидроксиметил)-3-гидрокси)пропиламид;
(Н)(CH3CO)-β-Nal-D-Cys-Pal-D-Trp-Lys-Val-Cys-2R, 3R-(2-гидроксиметил)-3-гидрокси)пропиламид;
(Н)(4-(2-гидроксиэтил)-1-пиперазинилацетил)-β-Nal-D-Cys-Раl-D-Тrр-Lys-Vаl-Сys-2R,3R-(2-гидроксиметил)-3-гидрокси)пропиламид;
(Н)(4-(2-гидроксиэтил)-1-пиперизинэтансyльфонил)-β-NaL-D-Сys-Раl-D-Тrр-Lys-Vаl-Сys-2R,3R-(2-гидроксиметил)-3-гидрокси)пропиламид;
Н2-β-Nal-D-Сys-Тyr-D-Тrр-Lys-Тhr-Сys-2R, 3R-(2-гидроксиметил)-3-гидрокси)пропиламид;
(Н)(CH3CO)-β-Nal-D-Cys-Tyr-D-Trp-Lys-Thr-Cys-2R, 3R-(2-гидроксиметил)-3-гидрокси)пропиламид;
(Н)(4-(2-гидроксиэтил)-1-пиперазинилацетил)-β-Nаl-D-Сys-Тyr-D-Тrр-Lys-Тhr-Сys-2R,3R-(2-гидроксиметил)-3-гидрокси)пропиламид;
(Н)(4-(2-гидроксиэтил)-1-пиперизинэтансyльфонил)-β-Nal-D-Сys-Тyr-D-Тrр-Lys-Тhr-Сys-2R,3R-(2-гидроксиметил)-3-гидрокси)пропиламид;
H2-β-Nal-D-Cys-Pal-D-Trp-Lys-Thr-Cys-2R, 3R-(2-гидpoкcиметил)-3-гидрокси)пропиламид;
(H)(CH3CO)-β-Nal-D-Cys-Pal-D-Trp-Lys-Thr-Cys-2R, 3R-(2-гидроксиметил)-3-гидрокси)пропиламид;
(H)(4-(2-гидроксиэтил)-1-пиперазинилацетил)-β-Nal-D-Cys-Pal-D-Trp-Lys-Thr-Cys-2R,3R-(2-гидpoкcимeтил)-3-гидpoкcи)пpoпиламид;
(H)(4-(2-гидpoкcиэтил)-1-пипepизинэтaнcyльфoнил)-β-Nal-D-Сys-Раl-D-Тrр-Lys-Thr-Сys-2R,3R-(2-гидроксиметил)-3-гидрокси)пропиламид;
Н2-Рhе-D-Сys-Тyr-D-Тrр-Lys-Vаl-Сys-2R, 3R-(2-гидроксиметил)-3-гидрокси)пропиламид;
(H)(CH3CO)-Phe-D-Cys-Tyr-D-Trp-Lys-Val-Cys-2R, 3R-(2-гидроксиметил)-3-гидрокси)пропиламид;
(H)(4-(2-гидроксиэтил)-1-пиперазинилацетил)-Phe-D-Cys-Tyr-D-Trp-Lys-Val-Cys-2R,3R-(2-гидpoкcимeтил)-3-гидpoкcи)прoпиламид;
(Н)(4-(2-гидроксиэтил)-1-пиперизинэтансyльфонил)-Phe-D-Сys-Тyr-D-Тrр-Lys-Vаl-Сys-2R,3R-(2-гидроксиметил)-3-гидрокси)пропиламид;
Н2-Рhе-D-Сys-Раl-D-Тrр-Lys-Vаl-Сys-2R, 3R-(2-гидроксиметил)-3-гидрокси)пропиламид;
(H)(CH3CO)-Phe-D-Cys-Pal-D-Trp-Lys-Val-Cys-2R, 3R-(2-гидроксиметил)-3-гидрокси)пропиламид;
(Н)(4-(2-гидроксиэтил)-1-пиперазинилацетил)-Phe-D-Cys-Раl-D-Тrр-Lys-Vаl-Сys-2R,3R-(2-гидроксиметил)-3-гидрокси)пропиламид;
(H)(4-(2-гидроксиэтил)-1-пиперизинэтансyльфонил)-Рhе-D-Cys-Раl-D-Тrр-Lys-Vаl-Сys-2R,3R-(2-гидроксиметил)-3-гидрокси)пропиламид;
H2-Phe-D-Cys-Tyr-D-Trp-Lys-Thr-Cys-2R, 3R-(2-гидроксиметил)-3-гидрокси)пропиламид;
(H)(CH3CO)-Phe-D-Cys-Tyr-D-Trp-Lys-Thr-Cys-2R, 3R-(2-гидроксиметил)-3-гидрокси)пропиламид;
(Н)(4-(2-гидроксиэтил)-1-пиперазинилацетил)-Phe-D-Cys-Тyr-D-Тrр-Lys-Тhr-Сys-2R,3R-(2-гидроксиметил)-3-гидрокси)пропиламид;
(Н)(4-(2-гидроксиэтил)-1-пиперизинэтансyльфонил)-Phe-3-Cys-Tyr-D-Trp-Lys-Thr-Cys-2R,3R-(2-гидроксиметил)-3-гидрокси)пропиламид;
Н2-Рhе-D-Сys-Раl-D-Тrр-Lys-Тhr-Сys-2R, 3R-(2-гидроксиметил)-3-гидрокси)пропиламид;
(H)(CH3CO)-Phe-D-Cys-Pal-D-Trp-Lys-Thr-Cys-2R, 3R-(2-гидроксиметил)-3-гидрокси)пропиламид;
(Н)(4-(2-гидроксиэтил)-1-пиперазинилацетил)-Phe-D-Cys-Pа1-D-Тгр-Lys-Тhr-Сys-2R,3R-(2-гидроксиметил)-3-гидрокси)пропиламид;
(Н)(4-(2-гидроксиэтил)-1-пиперизинэтансyльфонил)-Phe-D-Сys-Раl-D-Тrр-Lys-Тhr-Сys-2R,3R-(2-гидроксиметил)-3-гидрокси)пропиламид;
H2-β-Nal-D-Cys-Tyr-D-Trp-Lys-Val-Cys-2R-(2-нафтил)этиламид;
(H)(CH3CO)-β-Nal-D-Cys-Tyr-D-Trp-Lys-Val-Cys-2R-(2-нафтил)этиламид;
(Н)(4-(2-гидроксиэтил)-1-пиперазинилацетил)-β-Nal-D-Cys-Tyr-D-Trp-Lys-Val-Cys-2R-(2-нафтил)этиламид;
(Н)(4-(2-гидроксиэтил)-1-пиперизинэтансyльфонил)-β-Nal-D-Сys-Тyr-D-Тrр-Lys-Vаl-Сys-2R-(2-нафтил)этиламид;
Н2-β-Nal-D-Сys-Раl-D-Тrр-Lys-Vаl-Сys-2R-(2-нафтил)этиламид;
(Н)(CH3CO)-β-Nal-D-Cys-Pal-D-Trp-Lys-Val-Cys-2R-(2-нафтил)этиламид;
(Н)(4-(2-гидроксиэтил)-1-пиперазинилацетил)-β-Nаl-D-Сys-Pal-D-Trp-Lys-Val-Cys-2R-(2-нaфтил)этилaмид;
(Н)(4-(2-гидроксиэтил)-1-пиперизинэтансyльфонил)-β-Nal-D-Сys-Раl-D-Тrр-Lys-Vаl-Сys-2R-(2-нафтил)этиламид;
Н2-β-Nаl-D-Сys-Тyr-D-Тrр-Lys-Тhr-Сys-2R-(2-нафтил)этиламид;
(Н)(CH3CO)-β-Nal-D-Cys-Tyr-D-Trp-Lys-Thr-Cys-2R-(2-нафтил)этиламид;
(Н)(4-(2-гидроксиэтил)-1-пиперазинилацетил)-β-Nаl-D-Сys-Тyr-D-Тrр-Lys-Тhr-Сys-2R-(2-нафтил)этиламид;
(Н)(4-(2-гидроксиэтил)-1-пиперизинэтансyльфонил)-β-Nal-D-Сys-Тyr-D-Тrр-Lys-Тhг-Сys-2R-(2-нафтил)этиламид;
Н2-β-Nаl-D-Сys-Раl-D-Тrр-Lys-Тhr-Сys-2R-(2-нафтил)этиламид;
(Н)(CH3CO)-β-Nal-D-Cys-Pal-D-Trp-Lys-Thr-Cys-2R-(2-нафтил)этиламид;
(Н)(4-(2-гидроксиэтил)-1-пиперазинилацетил)-β-Nаl-D-Сys-Pal-D-Trp-Lys-Thr-Cys-2R-(2-нафтил)этиламид;
(Н)(4-(2-гидроксиэтил)-1-пиперизинэтансyльфонил)-β-Nаl-D-Cys-Pal-D-Trp-Lys-Thr-Cys-2R-(2-нафтил)этиламид;
H2-Phe-D-Cys-Tyr-D-Trp-Lys-Val-Cys-2R-(2-нафтил)этиламид;
(Н)(CH3CO)-Phe-D-Cys-Tyr-D-Trp-Lys-Val-Cys-2R-(2-нафтил)этиламид;
(Н)(4-(2-гидроксиэтил)-1-пиперазинилацетил)-Phe-D-Cys-Тyr-D-Тrр-Lys-Vаl-Сys-2R-(2-нафтил)этиламид;
(Н)(4-(2-гидроксиэтил)-1-пиперизинэтансyльфонил)-Phe-D-Сys-Тyr-D-Тrр-Lys-Vаl-Сys-2R-(2-нафтил)этиламид;
Н2-Рhe-D-Сys-Раl-D-Тrр-Lys-Vаl-Сys-2R-(2-нафтил)этиламид;
(Н)(СН3СО)-Рhе-D-Сys-Раl-D-Тrр-Lys-Vаl-Сys-2R-(2-нафтил)этиламид;
(Н)(4-(2-гидроксиэтил)-1-пиперазинилацетил)-Phe-D-Cys-Раl-D-Тrр-Lys-Vаl-Сys-2R-(2-нафтил)этиламид;
(Н)(4-(2-гидроксиэтил)-1-пиперизинэтансyльфонил)-Phe-D-Сys-Раl-D-Тrр-Lys-Vаl-Сys-2R-(2-нафтил)этиламид;
Н2-Рhе-D-Сys-Тyr-D-Тrр-Lys-Тhr-Сys-2R-(2-нафтил)этиламид;
(Н)(СН3СО)-Рhе-D-Сys-Тyr-D-Тrр-Lys-Тhr-Сys-2R-(2-нафтил)этиламид;
(Н)(4-(2-гидроксиэтил)-1-пиперазинилацетил)-Phe-D-Cys-Тyr-D-Тrр-Lys-Тhr-Сys-2R-(2-нафтил)этиламид;
(H)(4-(2-гидроксиэтил)-1-пиперизинэтансyльфонил)-Phe-D-Cys-Tyr-D-Trp-Lys-Thr-Cys-2R-(2-нафтил)этиламид;
H2-Phe-D-Cys-Pal-D-Trp-Lys-Thr-Cys-2R-(2-нафтил)этиламид;
(H)(CH3CO)-Phe-D-Cys-Pal-D-Trp-Lys-Thr-Cys-2R-(2-нафтил)этиламид;
(H)(4-(2-гидроксиэтил)-1-пиперазинилацетил)-Phe-D-Cys-Раl-D-Тrp-Lys-Тhr-Сys-2R-(2-нафтил)этиламид;
(Н)(4-(2-гидроксиэтил)-1-пиперизинэтансyльфонил)-Phe-D-Сys-Раl-D-Тrр-Lys-Тhr-Сys-2R-(2-нафтил)этиламид;
Н2-β-Nаl-D-Сys-Тyr-D-Тrр-Lys-Аbu-Сys-2R-(2-нафтил)этиламид;
Н2-Рhе-D-Сys-Тyr-D-Тrр-Lys-Аbu-Сys-2R-(2-нафтил)этиламид;
Н2-β-Nаl-D-Сys-Тyr-D-Тrр-Lys-Аbu-Сys-2R, 3R-(2-гидроксиметил)-3-гидрокси)пропиламид;
H2-Phe-D-Cys-Tyr-D-Trp-Lys-Abu-Cys-2R, 3R-(2-гидроксиметил)-3-гидрокси)пропиламид;
или его фармацевтически приемлемая соль.22. The compound according to claim 19 of the formula:
H 2 -β-Nal-D-Cys-Tyr-D-Trp-Lys-Val-Cys-2R, 3R- (2-hydroxymethyl) -3-hydroxy) propylamide;
(H) (CH 3 CO) -β-Nal-D-Cys-Tyr-D-Trp-Lys-Val-Cys-2R, 3R- (2-hydroxymethyl) -3-hydroxy) propylamide;
(H) (4- (2-hydroxyethyl) -1-piperazinyl acetyl) -β-Nal-D-Cys-Tyr-D-Trp-Lys-Val-Cys-2R, 3R- (2-hydroxymethyl) -3-hydroxy ) propylamide;
(H) (4- (2-hydroxyethyl) -1-piperizine ethanesulfonyl) -β-Nal-D-Cys-Tyr-D-Trp-Lys-Val-Cys-2R, 3R- (2-hydroxymethyl) -3-hydroxy a) propylamide;
H 2 -β-Nal-D-Cys-Pal-D-Trp-Lys-Val-Cys-2R, 3R- (2-hydroxymethyl) -3-hydroxy) propylamide;
(H) (CH 3 CO) -β-Nal-D-Cys-Pal-D-Trp-Lys-Val-Cys-2R, 3R- (2-hydroxymethyl) -3-hydroxy) propylamide;
(H) (4- (2-hydroxyethyl) -1-piperazinyl acetyl) -β-Nal-D-Cys-Pall-D-Trp-Lys-Val-Cys-2R, 3R- (2-hydroxymethyl) -3-hydroxy a) propylamide;
(H) (4- (2-hydroxyethyl) -1-piperizine ethanesulfonyl) -β-NaL-D-Cys-Pall-D-Trp-Lys-Val-Cys-2R, 3R- (2-hydroxymethyl) -3-hydroxy a) propylamide;
H 2 -β-Nal-D-Cys-Tyr-D-Trp-Lys-Thr-Cys-2R, 3R- (2-hydroxymethyl) -3-hydroxy) propylamide;
(H) (CH 3 CO) -β-Nal-D-Cys-Tyr-D-Trp-Lys-Thr-Cys-2R, 3R- (2-hydroxymethyl) -3-hydroxy) propylamide;
(H) (4- (2-hydroxyethyl) -1-piperazinylacetyl) -β-Nal-D-Cys-Tyr-D-Trp-Lys-Thr-Cys-2R, 3R- (2-hydroxymethyl) -3-hydroxy a) propylamide;
(H) (4- (2-hydroxyethyl) -1-piperizine ethanesulfonyl) -β-Nal-D-Cys-Tyr-D-Trp-Lys-Thr-Cys-2R, 3R- (2-hydroxymethyl) -3-hydroxy a) propylamide;
H 2 -β-Nal-D-Cys-Pal-D-Trp-Lys-Thr-Cys-2R, 3R- (2-hydroxymethyl) -3-hydroxy) propylamide;
(H) (CH 3 CO) -β-Nal-D-Cys-Pal-D-Trp-Lys-Thr-Cys-2R, 3R- (2-hydroxymethyl) -3-hydroxy) propylamide;
(H) (4- (2-hydroxyethyl) -1-piperazinylacetyl) -β-Nal-D-Cys-Pal-D-Trp-Lys-Thr-Cys-2R, 3R- (2-hydroxymethyl) -3-hydroxy a) propylamide;
(H) (4- (2-hydroxyethyl) -1-piperazine ethanesulfonyl) -β-Nal-D-Cys-Hal-D-Trp-Lys-Thr-Cys-2R, 3R- (2-hydroxymethyl) -3-hydroxy a) propylamide;
H 2 -Phe-D-Cys-Tyr-D-Trp-Lys-Val-Cys-2R, 3R- (2-hydroxymethyl) -3-hydroxy) propylamide;
(H) (CH 3 CO) -Phe-D-Cys-Tyr-D-Trp-Lys-Val-Cys-2R, 3R- (2-hydroxymethyl) -3-hydroxy) propylamide;
(H) (4- (2-hydroxyethyl) -1-piperazinylacetyl) -Phe-D-Cys-Tyr-D-Trp-Lys-Val-Cys-2R, 3R- (2-hydroximethyl) -3-hydroxy) propylamide ;
(H) (4- (2-hydroxyethyl) -1-piperizine ethanesulfonyl) -Phe-D-Cys-Tyr-D-Trp-Lys-Val-Cys-2R, 3R- (2-hydroxymethyl) -3-hydroxy) propylamide ;
H 2 -Phe-D-Cys-PAL-D-Trp-Lys-Val-Cys-2R, 3R- (2-hydroxymethyl) -3-hydroxy) propylamide;
(H) (CH 3 CO) -Phe-D-Cys-Pal-D-Trp-Lys-Val-Cys-2R, 3R- (2-hydroxymethyl) -3-hydroxy) propylamide;
(H) (4- (2-hydroxyethyl) -1-piperazinylacetyl) -Phe-D-Cys-Pall-D-Trp-Lys-Val-Cys-2R, 3R- (2-hydroxymethyl) -3-hydroxy) propylamide ;
(H) (4- (2-hydroxyethyl) -1-piperizine ethanesulfonyl) -Phe-D-Cys-PAL-D-Trp-Lys-Val-Cys-2R, 3R- (2-hydroxymethyl) -3-hydroxy) propylamide ;
H 2 -Phe-D-Cys-Tyr-D-Trp-Lys-Thr-Cys-2R, 3R- (2-hydroxymethyl) -3-hydroxy) propylamide;
(H) (CH 3 CO) -Phe-D-Cys-Tyr-D-Trp-Lys-Thr-Cys-2R, 3R- (2-hydroxymethyl) -3-hydroxy) propylamide;
(H) (4- (2-hydroxyethyl) -1-piperazinylacetyl) -Phe-D-Cys-Tyr-D-Trp-Lys-Thr-Cys-2R, 3R- (2-hydroxymethyl) -3-hydroxy) propylamide ;
(H) (4- (2-hydroxyethyl) -1-piperizine ethanesulfonyl) -Phe-3-Cys-Tyr-D-Trp-Lys-Thr-Cys-2R, 3R- (2-hydroxymethyl) -3-hydroxy) propylamide ;
H 2 -Phe-D-Cys-PAL-D-Trp-Lys-Thr-Cys-2R, 3R- (2-hydroxymethyl) -3-hydroxy) propylamide;
(H) (CH 3 CO) -Phe-D-Cys-Pal-D-Trp-Lys-Thr-Cys-2R, 3R- (2-hydroxymethyl) -3-hydroxy) propylamide;
(H) (4- (2-hydroxyethyl) -1-piperazinylacetyl) -Phe-D-Cys-Pa1-D-Trp-Lys-Thr-Cys-2R, 3R- (2-hydroxymethyl) -3-hydroxy) propylamide ;
(H) (4- (2-hydroxyethyl) -1-piperizine ethanesulfonyl) -Phe-D-Cys-Pall-D-Trp-Lys-Thr-Cys-2R, 3R- (2-hydroxymethyl) -3-hydroxy) propylamide ;
H 2 -β-Nal-D-Cys-Tyr-D-Trp-Lys-Val-Cys-2R- (2-naphthyl) ethylamide;
(H) (CH 3 CO) -β-Nal-D-Cys-Tyr-D-Trp-Lys-Val-Cys-2R- (2-naphthyl) ethylamide;
(H) (4- (2-hydroxyethyl) -1-piperazinyl acetyl) -β-Nal-D-Cys-Tyr-D-Trp-Lys-Val-Cys-2R- (2-naphthyl) ethylamide;
(H) (4- (2-hydroxyethyl) -1-piperizine ethanesulfonyl) -β-Nal-D-Cys-Tyr-D-Trp-Lys-Val-Cys-2R- (2-naphthyl) ethylamide;
H 2 -β-Nal-D-Cys-Pa-D-Trp-Lys-Val-Cys-2R- (2-naphthyl) ethylamide;
(H) (CH 3 CO) -β-Nal-D-Cys-Pal-D-Trp-Lys-Val-Cys-2R- (2-naphthyl) ethylamide;
(H) (4- (2-hydroxyethyl) -1-piperazinylacetyl) -β-Nal-D-Cys-Pal-D-Trp-Lys-Val-Cys-2R- (2-naphthyl) ethyl amide;
(H) (4- (2-hydroxyethyl) -1-piperizine ethanesulfonyl) -β-Nal-D-Cys-Pall-D-Trp-Lys-Val-Cys-2R- (2-naphthyl) ethylamide;
H 2 -β-Nal-D-Cys-Tyr-D-Trp-Lys-Thr-Cys-2R- (2-naphthyl) ethylamide;
(H) (CH 3 CO) -β-Nal-D-Cys-Tyr-D-Trp-Lys-Thr-Cys-2R- (2-naphthyl) ethylamide;
(H) (4- (2-hydroxyethyl) -1-piperazinylacetyl) -β-Nal-D-Cys-Tyr-D-Trp-Lys-Thr-Cys-2R- (2-naphthyl) ethylamide;
(H) (4- (2-hydroxyethyl) -1-piperizine ethanesulfonyl) -β-Nal-D-Cys-Tyr-D-Trp-Lys-Thg-Cys-2R- (2-naphthyl) ethylamide;
H 2 -β-Nal-D-Cys-Pall-D-Trp-Lys-Thr-Cys-2R- (2-naphthyl) ethylamide;
(H) (CH 3 CO) -β-Nal-D-Cys-Pal-D-Trp-Lys-Thr-Cys-2R- (2-naphthyl) ethylamide;
(H) (4- (2-hydroxyethyl) -1-piperazinyl acetyl) -β-Nal-D-Cys-Pal-D-Trp-Lys-Thr-Cys-2R- (2-naphthyl) ethylamide;
(H) (4- (2-hydroxyethyl) -1-piperizine ethanesulfonyl) -β-Nal-D-Cys-Pal-D-Trp-Lys-Thr-Cys-2R- (2-naphthyl) ethylamide;
H 2 -Phe-D-Cys-Tyr-D-Trp-Lys-Val-Cys-2R- (2-naphthyl) ethylamide;
(H) (CH 3 CO) -Phe-D-Cys-Tyr-D-Trp-Lys-Val-Cys-2R- (2-naphthyl) ethylamide;
(H) (4- (2-hydroxyethyl) -1-piperazinylacetyl) -Phe-D-Cys-Tyr-D-Trp-Lys-Val-Cys-2R- (2-naphthyl) ethylamide;
(H) (4- (2-hydroxyethyl) -1-piperizine ethanesulfonyl) -Phe-D-Cys-Tyr-D-Trp-Lys-Val-Cys-2R- (2-naphthyl) ethylamide;
H 2 -Phe-D-Cys-Pall-D-Trp-Lys-Val-Cys-2R- (2-naphthyl) ethylamide;
(H) (CH 3 CO) -Phe-D-Cys-Pall-D-Trp-Lys-Val-Cys-2R- (2-naphthyl) ethylamide;
(H) (4- (2-hydroxyethyl) -1-piperazinylacetyl) -Phe-D-Cys-Pall-D-Trp-Lys-Val-Cys-2R- (2-naphthyl) ethylamide;
(H) (4- (2-hydroxyethyl) -1-piperizine ethanesulfonyl) -Phe-D-Cys-Pall-D-Trp-Lys-Val-Cys-2R- (2-naphthyl) ethylamide;
H 2 -Phe-D-Cys-Tyr-D-Trp-Lys-Thr-Cys-2R- (2-naphthyl) ethylamide;
(H) (CH 3 CO) -Phe-D-Cys-Tyr-D-Trp-Lys-Thr-Cys-2R- (2-naphthyl) ethylamide;
(H) (4- (2-hydroxyethyl) -1-piperazinylacetyl) -Phe-D-Cys-Tyr-D-Trp-Lys-Thr-Cys-2R- (2-naphthyl) ethylamide;
(H) (4- (2-hydroxyethyl) -1-piperizine ethanesulfonyl) -Phe-D-Cys-Tyr-D-Trp-Lys-Thr-Cys-2R- (2-naphthyl) ethylamide;
H 2 -Phe-D-Cys-Pal-D-Trp-Lys-Thr-Cys-2R- (2-naphthyl) ethylamide;
(H) (CH 3 CO) -Phe-D-Cys-Pal-D-Trp-Lys-Thr-Cys-2R- (2-naphthyl) ethylamide;
(H) (4- (2-hydroxyethyl) -1-piperazinylacetyl) -Phe-D-Cys-Pall-D-Trp-Lys-Thr-Cys-2R- (2-naphthyl) ethylamide;
(H) (4- (2-hydroxyethyl) -1-piperizine ethanesulfonyl) -Phe-D-Cys-Pall-D-Trp-Lys-Thr-Cys-2R- (2-naphthyl) ethylamide;
H 2 -β-Nal-D-Cys-Tyr-D-Trp-Lys-Abu-Cys-2R- (2-naphthyl) ethylamide;
H 2 -Phe-D-Cys-Tyr-D-Trp-Lys-Abu-Cys-2R- (2-naphthyl) ethylamide;
H 2 -β-Nal-D-Cys-Tyr-D-Trp-Lys-Abu-Cys-2R, 3R- (2-hydroxymethyl) -3-hydroxy) propylamide;
H 2 -Phe-D-Cys-Tyr-D-Trp-Lys-Abu-Cys-2R, 3R- (2-hydroxymethyl) -3-hydroxy) propylamide;
or its pharmaceutically acceptable salt.
H2-Phe-D-Phe-Tyr-D-Trp-Lys-Thr-Phe-Thr-NH2;
H2-Phe-D-Phe-Tyr-D-Trp-Lys-Val-Phe-Thr-NH2;
Н2-Phe-Cpa-Tyr-D-Trp-Lys-Val-Phe-Thr-NH2;
Н2-β-Nal-D-Cpa-Tyr-D-Trp-Lys-Val-Phe-Thr-NH2 (аналог )
(Н) (СН3СО)-β-Nal-D-Cpa-Tyr-D-Trp-Lys-Val-Phe-Thr-NH2;
(Н)(4-(2-гидроксиэтил)-1-пиперазинилацетил-)-β-Nal-D-Cpa-Tyr-D-Trp-Lys-Val-Phe-Thr-NH2;
(Н)(4-(2-гидроксиэтил)-1-пиперазинэтансульфонил)-β-Nal-D-Cpa-Tyr-D-Trp-Lys-Val-Phe-Thr-NH2;
Н2-β-Nal-D-Cpa-Pal-D-Trp-Lys-Val-Phe-Thr-NH2;
(Н) (СН3СО)-β-Nal-D-Cpa-Pal-D-Trp-Lys-Val-Phe-Thr-NH2;
(Н)(4-(2-гидроксиэтил)-1-пиперазинилацетил-)-β-Nal-D-Cpa-Pal-D-Trp-Lys-Val-Phe-Thr-NH2;
(Н)(4-(2-гидроксиэтил)-1-пиперазинэтансульфонил)-β-Nal-D-Cpa-Pal-D-Trp-Lys-Val-Phe-Thr-NH2;
Н2-β-Nal-D-Cpa-Tyr-D-Trp-Lys-Thr-Phe-Thr-NH2;
(Н) (СН3СО)-β-Nal-D-Cpa-Tyr-D-Trp-Lys-Thr-Phe-Thr-NH2;
(Н) (4-(2-гидроксиэтил)-1-пиперазинилацетил)-β-Nal-D-Cpa-Tyr-D-Trp-Lys-Thr-Phe-Thr-NH2;
(Н)(4-(2-гидроксиэтил)-1-пиперазинэтансульфонил)-β-Nal-D-Cpa-Tyr-D-Trp-Lys-Thr-Phe-Thr-NH2;
Н2-β-Nal-D-Cpa-Pal-D-Trp-Lys-Thr-Phe-Thr-NH2;
(Н) (СН3СО)-β-Nal-D-Cpa-Pal-D-Trp-Lys-Thr-Phe-Thr-NH2;
(Н) (4-(2-гидроксиэтил)-1-пиперазинилацетил)-β-Nal-D-Cpa-Pal-D-Trp-Lys-Thr-Phe-Thr-NH2;
(Н)(4-(2-гидроксиэтил)-1-пиперазинэтансульфонил)-β-Nal-D-Cpa-Pal-D-Trp-Lys-Thr-Phe-Thr-NH2;
Н2-β-Nal-D-Cpa-Tyr-D-Trp-Lys-Val-Phe-β-Nal-NH2;
(Н) (СН3СО)-β-Nal-D-Cpa-Tyr-D-Trp-Lys-Val-Phe-β-Nal-NH2;
(Н) (4-(2-гидроксиэтил)-1-пиперазинилацетил)-β-Nal-D-Cpa-Tyr-D-Trp-Lys-Val-Phe-β-Nal-NH2;
(Н)(4-(2-гидроксиэтил)-1-пиперазинэтансульфонил)-β-Nal-D-Cpa-Tyr-D-Trp-Lys-Val-Phe-β-Nal-NH2;
Н2-β-Nal-D-Cpa-Tyr-D-Trp-Lys-Val-Phe-β-Nal-NH2; или
Н2-β-Nal-D-Cpa-Tyr-D-Trp-Lys-Val-Phe-Thr-NH2;
или его фармацевтически приемлемая соль.27. The compound according to claim 25, of the formula:
H 2 -Phe-D-Phe-Tyr-D-Trp-Lys-Thr-Phe-Thr-NH 2 ;
H 2 -Phe-D-Phe-Tyr-D-Trp-Lys-Val-Phe-Thr-NH 2 ;
H 2 -Phe-Cpa-Tyr-D-Trp-Lys-Val-Phe-Thr-NH 2 ;
H 2 -β-Nal-D-Cpa-Tyr-D-Trp-Lys-Val-Phe-Thr-NH 2 (analog)
(H) (CH 3 CO) -β-Nal-D-Cpa-Tyr-D-Trp-Lys-Val-Phe-Thr-NH 2 ;
(H) (4- (2-hydroxyethyl) -1-piperazinylacetyl -) - β-Nal-D-Cpa-Tyr-D-Trp-Lys-Val-Phe-Thr-NH 2 ;
(H) (4- (2-hydroxyethyl) -1-piperazine ethanesulfonyl) -β-Nal-D-Cpa-Tyr-D-Trp-Lys-Val-Phe-Thr-NH 2 ;
H 2 -β-Nal-D-Cpa-Pal-D-Trp-Lys-Val-Phe-Thr-NH 2 ;
(H) (CH 3 CO) -β-Nal-D-Cpa-Pal-D-Trp-Lys-Val-Phe-Thr-NH 2 ;
(H) (4- (2-hydroxyethyl) -1-piperazinylacetyl -) - β-Nal-D-Cpa-Pal-D-Trp-Lys-Val-Phe-Thr-NH 2 ;
(H) (4- (2-hydroxyethyl) -1-piperazine ethanesulfonyl) -β-Nal-D-Cpa-Pal-D-Trp-Lys-Val-Phe-Thr-NH 2 ;
H 2 -β-Nal-D-Cpa-Tyr-D-Trp-Lys-Thr-Phe-Thr-NH 2 ;
(H) (CH 3 CO) -β-Nal-D-Cpa-Tyr-D-Trp-Lys-Thr-Phe-Thr-NH 2 ;
(H) (4- (2-hydroxyethyl) -1-piperazinyl acetyl) -β-Nal-D-Cpa-Tyr-D-Trp-Lys-Thr-Phe-Thr-NH 2 ;
(H) (4- (2-hydroxyethyl) -1-piperazine ethanesulfonyl) -β-Nal-D-Cpa-Tyr-D-Trp-Lys-Thr-Phe-Thr-NH 2 ;
H 2 -β-Nal-D-Cpa-Pal-D-Trp-Lys-Thr-Phe-Thr-NH 2 ;
(H) (CH 3 CO) -β-Nal-D-Cpa-Pal-D-Trp-Lys-Thr-Phe-Thr-NH 2 ;
(H) (4- (2-hydroxyethyl) -1-piperazinylacetyl) -β-Nal-D-Cpa-Pal-D-Trp-Lys-Thr-Phe-Thr-NH 2 ;
(H) (4- (2-hydroxyethyl) -1-piperazine ethanesulfonyl) -β-Nal-D-Cpa-Pal-D-Trp-Lys-Thr-Phe-Thr-NH 2 ;
H 2 -β-Nal-D-Cpa-Tyr-D-Trp-Lys-Val-Phe-β-Nal-NH 2 ;
(H) (CH 3 CO) -β-Nal-D-Cpa-Tyr-D-Trp-Lys-Val-Phe-β-Nal-NH 2 ;
(H) (4- (2-hydroxyethyl) -1-piperazinyl acetyl) -β-Nal-D-Cpa-Tyr-D-Trp-Lys-Val-Phe-β-Nal-NH 2 ;
(H) (4- (2-hydroxyethyl) -1-piperazine ethanesulfonyl) -β-Nal-D-Cpa-Tyr-D-Trp-Lys-Val-Phe-β-Nal-NH 2 ;
H 2 -β-Nal-D-Cpa-Tyr-D-Trp-Lys-Val-Phe-β-Nal-NH 2 ; or
H 2 -β-Nal-D-Cpa-Tyr-D-Trp-Lys-Val-Phe-Thr-NH 2 ;
or its pharmaceutically acceptable salt.
Н2-D-β-Nal-D-Cpa-Phe-D-Trp-Lys-Val-Phe-Thr-NН2;
Н2-D-β-Nal-D-Phe-Tyr-D-Trp-Lys-Thr-Phe-Thr-NН2;
Н2-D-Phe-D-Phe-Tyr-D-Trp-Lys-Val-Phe-Thr-NН2;
Н2-D-β-Nal-D-Cpa-Tyr-D-Trp-Lys-Val-Phe-Thr-NН2; или
Н2-D-β-Nal-D-Cpa-Tyr-D-Trp-Lys-Val-Phe-β-Nal-NН2
или его фармацевтически приемлемая соль.31. The compound according to claim 29 of the formula:
H 2 -D-β-Nal-D-Cpa-Phe-D-Trp-Lys-Val-Phe-Thr-NH 2 ;
H 2 -D-β-Nal-D-Phe-Tyr-D-Trp-Lys-Thr-Phe-Thr-NH 2 ;
H 2 -D-Phe-D-Phe-Tyr-D-Trp-Lys-Val-Phe-Thr-NH 2 ;
H 2 -D-β-Nal-D-Cpa-Tyr-D-Trp-Lys-Val-Phe-Thr-NH 2 ; or
H 2 -D-β-Nal-D-Cpa-Tyr-D-Trp-Lys-Val-Phe-β-Nal-NH 2
or its pharmaceutically acceptable salt.
Applications Claiming Priority (6)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US3235896P | 1996-12-04 | 1996-12-04 | |
US76067296A | 1996-12-04 | 1996-12-04 | |
US60/032,358 | 1996-12-04 | ||
US08/760,672 | 1996-12-04 | ||
US08/855,204 | 1997-05-13 | ||
US08/855,204 US6262229B1 (en) | 1996-12-04 | 1997-05-13 | Somatostatin antagonists |
Publications (2)
Publication Number | Publication Date |
---|---|
RU99114018A true RU99114018A (en) | 2001-05-20 |
RU2179172C2 RU2179172C2 (en) | 2002-02-10 |
Family
ID=27364103
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
RU99114018/04A RU2179172C2 (en) | 1996-12-04 | 1997-12-04 | Somatostatin receptor antagonists |
Country Status (17)
Country | Link |
---|---|
EP (1) | EP0956296B1 (en) |
JP (2) | JP4124820B2 (en) |
KR (1) | KR100479149B1 (en) |
AT (1) | ATE330966T1 (en) |
AU (1) | AU728224B2 (en) |
BR (1) | BR9714376A (en) |
CA (1) | CA2274144C (en) |
DE (1) | DE69736193T2 (en) |
ES (1) | ES2264174T3 (en) |
HU (1) | HUP0003396A3 (en) |
IL (1) | IL130166A0 (en) |
MX (1) | MXPA99004944A (en) |
NZ (1) | NZ335879A (en) |
PL (1) | PL334089A1 (en) |
RU (1) | RU2179172C2 (en) |
TW (1) | TW575582B (en) |
WO (1) | WO1998024807A2 (en) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
RU2525468C2 (en) * | 2009-05-07 | 2014-08-20 | БКН Пептидес, С.А. | Peptide ligands of somatostatine receptors |
Families Citing this family (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6864234B1 (en) | 1999-06-25 | 2005-03-08 | Societe De Conseils De Recherches Et D'applications Scientifiques, S.A.S. | Somatostatin agonists |
HUP0201696A3 (en) * | 1999-06-25 | 2002-10-28 | Sod Conseils Rech Applic | Cyclic peptides, pharmaceutical compositions comprising thereof and their use |
ES2306766T3 (en) | 2001-03-08 | 2008-11-16 | The Administrators Of The Tulane Educational Fund | SOMATOSTATINE ANTAGONISTS. |
IL158051A0 (en) * | 2001-04-09 | 2004-03-28 | Univ Tulane | Somatostatin agonists |
BRPI0717135B8 (en) * | 2006-10-16 | 2021-05-25 | Salk Inst Biological Studies | cyclic somatostatin peptide antagonist and pharmaceutical composition |
US8691761B2 (en) | 2006-10-16 | 2014-04-08 | Jean E. F. Rivier | Somatostatin receptor 2 antagonists |
WO2011151782A1 (en) | 2010-06-02 | 2011-12-08 | Preglem Sa | A role for somatostatin to modulate initiation of follicular growth in the human ovary |
EP2399931A1 (en) * | 2010-06-22 | 2011-12-28 | Ipsen Pharma S.A.S. | New octapeptide compounds and their therapeutic use |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
HUT42101A (en) * | 1985-01-07 | 1987-06-29 | Sandoz Ag | Process for preparing stomatostatine derivatives and pharmaceutical compositions containing such compounds |
US4904642A (en) * | 1985-09-12 | 1990-02-27 | The Administrators Of The Tulane Educational Fund | Therapeutic somatostatin analogs |
US4853371A (en) * | 1986-06-17 | 1989-08-01 | The Administrators Of The Tulane Educational Fund | Therapeutic somatostatin analogs |
US5073541A (en) * | 1987-11-18 | 1991-12-17 | Administrators Of The Tulane Educational Fund | Treatment of small cell lung cancer with somatostatin analogs |
US5633263A (en) * | 1989-04-26 | 1997-05-27 | The Administrators Of The Tulane Educational Fund | Linear somatostatin analogs |
JP2882679B2 (en) * | 1989-04-26 | 1999-04-12 | ジ・アドミニストレーターズ・オブ・ザ・ツーレイン・エデュケイショナル・ファンド | Linear somatostatin analog |
US5708135A (en) * | 1995-09-29 | 1998-01-13 | Biomeasure Incorporated | Cyclic peptide analogs of somatostatin |
-
1997
- 1997-12-04 AT AT97949758T patent/ATE330966T1/en not_active IP Right Cessation
- 1997-12-04 DE DE69736193T patent/DE69736193T2/en not_active Expired - Lifetime
- 1997-12-04 TW TW86118262A patent/TW575582B/en not_active IP Right Cessation
- 1997-12-04 IL IL13016697A patent/IL130166A0/en unknown
- 1997-12-04 KR KR10-1999-7004835A patent/KR100479149B1/en not_active IP Right Cessation
- 1997-12-04 BR BR9714376A patent/BR9714376A/en unknown
- 1997-12-04 MX MXPA99004944A patent/MXPA99004944A/en unknown
- 1997-12-04 HU HU0003396A patent/HUP0003396A3/en unknown
- 1997-12-04 WO PCT/US1997/022251 patent/WO1998024807A2/en active IP Right Grant
- 1997-12-04 PL PL97334089A patent/PL334089A1/en unknown
- 1997-12-04 EP EP97949758A patent/EP0956296B1/en not_active Expired - Lifetime
- 1997-12-04 CA CA002274144A patent/CA2274144C/en not_active Expired - Lifetime
- 1997-12-04 NZ NZ335879A patent/NZ335879A/en unknown
- 1997-12-04 RU RU99114018/04A patent/RU2179172C2/en not_active IP Right Cessation
- 1997-12-04 AU AU76248/98A patent/AU728224B2/en not_active Ceased
- 1997-12-04 ES ES97949758T patent/ES2264174T3/en not_active Expired - Lifetime
- 1997-12-04 JP JP52580198A patent/JP4124820B2/en not_active Expired - Lifetime
-
2007
- 2007-12-11 JP JP2007319238A patent/JP4264762B2/en not_active Expired - Lifetime
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
RU2525468C2 (en) * | 2009-05-07 | 2014-08-20 | БКН Пептидес, С.А. | Peptide ligands of somatostatine receptors |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
RU99114018A (en) | SOMATOSTATIN ANTAGONISTS | |
DE69332826T2 (en) | OPIOID PEPTIDE | |
IN163758B (en) | ||
RU2008104802A (en) | Melanocortin receptor ligands | |
RU99123619A (en) | GNRH ANTAGONISTS MODIFIED IN POSITIONS 5 AND 6 | |
EP0029579A1 (en) | Polypeptides, processes for their production, pharmaceutical compositions comprising said polypeptides and their use | |
US9133262B2 (en) | Somatostatin antagonists | |
ATE78831T1 (en) | BIOLOGICALLY ACTIVE LYSINE CONTAINING OCTAPEPTIDES. | |
EP0514210B1 (en) | GRF analogs (Growth Hormone Releasing Factors) | |
RU2003132548A (en) | SOMATOSTATIN AGONISTS | |
CN101072791B (en) | S-alkyl-sulphenyl protection groups in solid-phase synthesis | |
RU2001117218A (en) | ANTAGONISTIC ANALOGUES OF RELEASING HORMONE OF GROWTH HORMONE (GH-RH), INHIBITING INSULIN-LIKE GROWTH FACTORS (IGF-I and-II) | |
KR910000178A (en) | Arthritis Treatment | |
NZ335879A (en) | Somatostatin antagonist peptides having a D-amino acid at the second residue | |
US5422341A (en) | Motilin-like polypeptides with gastrointestinal motor stimulating activity | |
EP0842193B1 (en) | Somatostatin-analogous cyclic peptides with inhibitory activity on growth hormone | |
RU2002101732A (en) | Somatostatin Agonists | |
WO1997037675A1 (en) | Prolonging survival of transplanted pancreatic cells | |
Hirst et al. | Non-reducible cyclic, and azaphenylalanyl6 analogues of somatostatin | |
RU98108419A (en) | CYCLIC PEPTIDE ANALOGUES OF SOMATOSTATIN | |
RU97107460A (en) | NEW PEPTIDES WITH IMMUNOMODULATORY ACTION | |
CA2022865A1 (en) | Analogues of 8-d-homoarginine vasopressin |